Why Cronos Group (TSX:CRON) Is Still Too Expensive, Even at $14/Share

At a valuation of 16 times forward earnings, Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) will have to execute its CBD strategy flawlessly to justify its valuation.

The deepening cannabis rout has brought down valuations across the sector, and even lavish names like Cronos Group (TSX: CRON)(NASDAQ: CRON) are beginning to look a lot more attractive, now that they’re trading at half of where they used to be. However, Cronos’s market cap only tells part of the story: even at these levels, Cronos remains a richly valued stock, whose near-term future hinges almost entirely on its CBD ambitions.

Last quarter was largely in line

Cronos delivered no surprises in the second quarter, with total kilos sold climbing to 1,584 up from 1,111 kilos in Q1 of 2019. As far as prices go, Cronos managed to outperform its peers, with average net selling price for dried cannabis climbing to $6.19/gram from $5.14/gram in the same period, and average net selling price of oils also rising to $7.69 from $7.16/gram.

The increase in kilos sold and realized prices translated to net revenues of $10.2 million, which works out to a 58% sequential increase. While these numbers are certainly laudable, bear in mind that Cronos trades at 16 times consensus sales. That means that if you buy Cronos, even at these levels, you are paying $16 for every $1 of expected revenues that Cronos will make, which is a very lavish price to pay, considering that names like Canopy Growth trade at roughly 10 times forward sales.

So, what exactly are you paying for when it comes to Cronos? Quite simply, CBD.

Will CBD be Cronos’s key to domination?

In July, Cronos announced that it would be entering the U.S. CBD market in the next six to 12 months. With Wall Street analysts calling for a $16 billion valuation in 2025 for the CBD space south of the border, it’s easy to see why Cronos’s has caught the attention of investors.

Moreover, Cronos recently announced intentions to acquire Redwood Holding Group, owner of popular CBD brand Lord Jones, which sells CBD-infused gummies, oils, topical lotions, and bath salts. The $300 million acquisition, which will be mostly paid in cash, signals Cronos’s dedication towards gaining a U.S. foothold — a fact that is made even more bullish, given that Cronos’s has the full backing and scale of Altria behind it, through their lucrative partnership arrangement.

But is CBD really worth that much?

While last quarter’s sales came in above estimates, $10.2 million is still a fraction of names like Canopy, which delivered nine times that amount, even on a weak quarter. Internationally, we also see competitors like Aphria branch out into lucrative European markets, whose growth mirrors that of the U.S. CBD space.

And while the Altria partnership grants Cronos unprecedented scale and branding expertise, I just cannot justify Cronos’s extremely premium valuation.

So, despite the recent selloff, I feel that Cronos’s future is too predicated on the flawless execution of its CBD strategy, and because of that, I cannot recommend buying Cronos, even at these prices.

Fool contributor Victoria Matsepudra has shares of Canopy Growth Corp.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »